Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,572 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Epigenetic Identity in AML Depends on Disruption of Nonpromoter Regulatory Elements and Is Affected by Antagonistic Effects of Mutations in Epigenetic Modifiers.
Glass JL, Hassane D, Wouters BJ, Kunimoto H, Avellino R, Garrett-Bakelman FE, Guryanova OA, Bowman R, Redlich S, Intlekofer AM, Meydan C, Qin T, Fall M, Alonso A, Guzman ML, Valk PJM, Thompson CB, Levine R, Elemento O, Delwel R, Melnick A, Figueroa ME. Glass JL, et al. Cancer Discov. 2017 Aug;7(8):868-883. doi: 10.1158/2159-8290.CD-16-1032. Epub 2017 Apr 13. Cancer Discov. 2017. PMID: 28408400 Free PMC article.
Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms.
Dunbar AJ, Bowman RL, Park YC, O'Connor K, Izzo F, Myers RM, Karzai A, Zaroogian Z, Kim WJ, Fernández-Maestre I, Waarts MR, Nazir A, Xiao W, Codilupi T, Brodsky M, Farina M, Cai L, Cai SF, Wang B, An W, Yang JL, Mowla S, Eisman SE, Hanasoge Somasundara AV, Glass JL, Mishra T, Houston R, Guzzardi E, Martinez Benitez AR, Viny AD, Koche RP, Meyer SC, Landau DA, Levine RL. Dunbar AJ, et al. Among authors: glass jl. Cancer Discov. 2024 May 1;14(5):737-751. doi: 10.1158/2159-8290.CD-22-0952. Cancer Discov. 2024. PMID: 38230747 Free PMC article.
PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.
Patel AJ, Warda S, Maag JLV, Misra R, Miranda-Román MA, Pachai MR, Lee CJ, Li D, Wang N, Bayshtok G, Fishinevich E, Meng Y, Wong EWP, Yan J, Giff E, Pappalardi MB, McCabe MT, Fletcher JA, Rudin CM, Chandarlapaty S, Scandura JM, Koche RP, Glass JL, Antonescu CR, Zheng D, Chen Y, Chi P. Patel AJ, et al. Among authors: glass jl. Cancer Discov. 2022 Sep 2;12(9):2120-2139. doi: 10.1158/2159-8290.CD-21-1671. Cancer Discov. 2022. PMID: 35789380 Free PMC article.
Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML.
Stahl M, Menghrajani K, Derkach A, Chan A, Xiao W, Glass J, King AC, Daniyan AF, Famulare C, Cuello BM, Horvat TZ, Abdel-Wahab O, Levine RL, Viny AD, Stein EM, Cai SF, Roshal M, Tallman MS, Goldberg AD. Stahl M, et al. Among authors: glass j. Blood Adv. 2021 Mar 9;5(5):1552-1564. doi: 10.1182/bloodadvances.2020003734. Blood Adv. 2021. PMID: 33687434 Free PMC article.
The prognosis and durable clearance of RAS mutations in patients with acute myeloid leukemia receiving induction chemotherapy.
Ball BJ, Hsu M, Devlin SM, Arcila M, Roshal M, Zhang Y, Famulare CA, Goldberg AD, Cai SF, Dunbar A, Epstein-Peterson Z, Menghrajani KN, Glass JL, Taylor J, Viny AD, Giralt SS, Gyurkocza B, Shaffer BC, Tamari R, Levine RL, Tallman MS, Stein EM. Ball BJ, et al. Among authors: glass jl. Am J Hematol. 2021 May 1;96(5):E171-E175. doi: 10.1002/ajh.26146. Epub 2021 Mar 24. Am J Hematol. 2021. PMID: 33650111 Free PMC article. No abstract available.
Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant.
Bewersdorf JP, Derkach A, Gowda L, Menghrajani K, DeWolf S, Ruiz JD, Ponce DM, Shaffer BC, Tamari R, Young JW, Jakubowski AA, Gyurkocza B, Chan A, Xiao W, Glass J, King AC, Cai SF, Daniyan A, Famulare C, Cuello BM, Podoltsev NA, Roshal M, Giralt S, Perales MA, Seropian S, Cho C, Zeidan AM, Prebet T, Stein EM, Tallman MS, Goldberg AD, Stahl M. Bewersdorf JP, et al. Among authors: glass j. Leuk Lymphoma. 2021 Dec;62(14):3394-3401. doi: 10.1080/10428194.2021.1966788. Epub 2021 Sep 3. Leuk Lymphoma. 2021. PMID: 34477024 Free PMC article.
Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia.
Stahl M, Derkach A, Farnoud N, Bewersdorf JP, Robinson T, Famulare C, Cho C, Devlin S, Menghrajani K, Patel MA, Cai SF, Miles LA, Bowman RL, Geyer MB, Dunbar A, Epstein-Peterson ZD, McGovern E, Schulman J, Glass JL, Taylor J, Viny AD, Stein EM, Getta B, Arcila ME, Gao Q, Barker J, Shaffer BC, Papadopoulos EB, Gyurkocza B, Perales MA, Abdel-Wahab O, Levine RL, Giralt SA, Zhang Y, Xiao W, Pai N, Papaemmanuil E, Tallman MS, Roshal M, Goldberg AD. Stahl M, et al. Among authors: glass jl. Am J Hematol. 2023 Jan;98(1):79-89. doi: 10.1002/ajh.26757. Epub 2022 Oct 31. Am J Hematol. 2023. PMID: 36251406 Free PMC article.
Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in IDH2- and TET2-Mutant Acute Myeloid Leukemia.
Shih AH, Meydan C, Shank K, Garrett-Bakelman FE, Ward PS, Intlekofer AM, Nazir A, Stein EM, Knapp K, Glass J, Travins J, Straley K, Gliser C, Mason CE, Yen K, Thompson CB, Melnick A, Levine RL. Shih AH, et al. Among authors: glass j. Cancer Discov. 2017 May;7(5):494-505. doi: 10.1158/2159-8290.CD-16-1049. Epub 2017 Feb 13. Cancer Discov. 2017. PMID: 28193779 Free PMC article.
1,572 results